Anti-TNFα in inflammatory bowel disease: from originators to biosimilars

The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated inflammatory bowel disease (IBD) treatment and increased medical costs. The recent expiration of patents of some anti-TNFα biologics (such as infliximab and adalimumab) facilitated the development of biosimilar...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Zhen Zeng, Hao Lin, Mingshan Jiang, Jing Yuan, Xi Li, Yongbin Jia, Li Yang, Hu Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	biosimilars originators anti-TNFα biologics inflammatory bowel disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1424606/full

Similar Items

Commentary: Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
by: Yingjie Liu, et al.
Published: (2025-07-01)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
by: Claudia Fabiani, et al.
Published: (2019-12-01)

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study
by: Fanny Alcira Reyes Neira, et al.
Published: (2025-02-01)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
by: Magdalena Kaniewska, et al.
Published: (2020-11-01)

Position statement on the use of biosimilars in inflammatory bowel disease
by: Emanuel Burri, et al.
Published: (2019-12-01)

Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis
by: Rachel C. Ruda, et al.
Published: (2023-12-01)

Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice
by: Dorota Waz, et al.
Published: (2025-01-01)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
by: Martina Burlando, et al.
Published: (2022-10-01)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
by: Roy Fleischmann, et al.
Published: (2020-01-01)

Optimizing development of anti-TNFα biosimilars based on 10 years’ experience
by: Cecil Nick
Published: (2025-02-01)

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain
by: Teresa Barcina Lacosta, et al.
Published: (2023-01-01)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
by: Evelien Moorkens, et al.
Published: (2020-10-01)

Patent and Regulatory Landscape of Biosimilars in the United States and Europe: Implications for Advancing the Domestic Biosimilar Industry with a Focus on Anti-TNF-α Biopharmaceuticals
by: Tae-Kwon Kim, et al.
Published: (2025-06-01)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
by: Al Sulais E, et al.
Published: (2020-01-01)

The Effects of a High-Fat Diet on Inflammatory Bowel Disease
by: Yuan Dang, et al.
Published: (2023-05-01)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
by: Giammarco Mocci, et al.
Published: (2022-07-01)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
by: Bas J. M. Peters, et al.
Published: (2021-02-01)

Anti-tumor necrosis factor α: originators <i>versus</i> biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
by: C. Gioia, et al.
Published: (2023-12-01)

Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study
by: Guillaume Larid, et al.
Published: (2022-10-01)

Switching between Originators and Biosimilars in Dermatology: A Systematic Review of Real-World Clinical Studies
by: Maria Maddalena Nicoletti, et al.
Published: (2023-04-01)

Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary
by: Richard H. Parrish
Published: (2021-06-01)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
by: Magdalena Kaniewska, et al.
Published: (2019-12-01)

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
by: Sang Hyoung Park, et al.
Published: (2020-01-01)

Adalimumab Biosimilars Demonstrate Long-Term Durability and Cost-Effectiveness in Paediatric Inflammatory Bowel Disease: A Real-World Two-Centre European Cohort Study
by: Ancona S, et al.
Published: (2025-04-01)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
by: Tomoo Nakagawa, et al.
Published: (2019-10-01)

The Perception among Israeli Gastroenterologists Regarding Treatment of Patients with Biosimilar Medications
by: Vered Richter, et al.
Published: (2023-03-01)

Evaluation of rheumatologists’ knowledge of biosimilars
by: Thayane Furtado Rolim Lima, et al.
Published: (2025-07-01)

Plasma Epstein-Barr Virus DNA load for diagnostic and prognostic assessment in intestinal Epstein-Barr Virus infection
by: Chunxiang Ma, et al.
Published: (2025-01-01)

Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers
by: Eva Dokoupilová, et al.
Published: (2024-06-01)

Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest
by: Natalia Kirsten, et al.
Published: (2022-09-01)

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study
by: Fanny Reyes-Neira, et al.
Published: (2025-10-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease
by: Kerry A. Ryan, et al.
Published: (2024-10-01)

Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
by: V. Shobha, et al.
Published: (2019-07-01)

Biosimilars Would Reduce Health Care Costs But Are Yet Poorly Known – Patient Survey Study Among Biological Medicine Users
by: Pölkki M, et al.
Published: (2024-02-01)

Aseptic abscess syndrome: a case report of a patient achieving remission with both infliximab originator and biosimilar administered at varied intervals
by: Federica Maria Ucci, et al.
Published: (2024-12-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020-12-01)

Biosimilar insulins in international and domestic practice of pharmacist
by: I. O. Vlasenko, et al.
Published: (2022-02-01)